Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 299.11M | 207.98M | 140.90M | 107.30M | 81.11M |
Gross Profit | 136.22M | 91.35M | 59.53M | 51.15M | 27.71M |
EBITDA | -253.30M | -174.14M | -117.73M | -118.88M | -873.32M |
Net Income | -237.03M | -191.69M | -123.16M | -143.65M | -877.05M |
Balance Sheet | |||||
Total Assets | 1.67B | 1.90B | 1.78B | 1.80B | 350.30M |
Cash, Cash Equivalents and Short-Term Investments | 684.63M | 945.71M | 1.33B | 1.52B | 192.32M |
Total Debt | 328.42M | 281.92M | 75.54M | 48.57M | 31.47M |
Total Liabilities | 527.47M | 499.98M | 188.33M | 85.85M | 68.96M |
Stockholders Equity | 1.14B | 1.40B | 1.59B | 1.72B | 281.33M |
Cash Flow | |||||
Free Cash Flow | -322.41M | -371.44M | -317.52M | -234.71M | -72.38M |
Operating Cash Flow | -229.12M | -267.23M | -188.77M | -197.85M | -64.29M |
Investing Cash Flow | -181.19M | -324.81M | -88.70M | -56.60M | 33.53M |
Financing Cash Flow | 33.78M | 190.55M | 23.51M | 1.60B | 207.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% | |
55 Neutral | €5.47B | ― | -10.43% | ― | 36.76% | 42.89% | |
54 Neutral | HK$1.45B | ― | -8.64% | ― | -20.99% | 45.74% | |
52 Neutral | HK$3.06B | ― | -2.19% | ― | 5.32% | 89.43% | |
49 Neutral | HK$768.61M | ― | -18.64% | ― | 41.62% | -22.27% | |
46 Neutral | HK$1.27B | ― | -27.82% | ― | -6.12% | 0.43% |
Suzhou Basecare Medical Corp. Ltd. announced changes to its Nomination Committee to align with the revised Corporate Governance Code effective from July 1, 2025. The appointment of Ms. Jiang Junchao and Dr. Yeung Shu Biu William as new members is expected to enhance the company’s governance structure and compliance with regulatory requirements.
Suzhou Basecare Medical Corporation Limited has established a Nomination Committee as a specialized body under its Board to oversee the selection of candidates for directors and senior management positions. This move is designed to improve the company’s corporate governance by ensuring a well-structured and rationalized board composition, which is expected to positively impact its operational efficiency and strategic decision-making.
Suzhou Basecare Medical Corp. Ltd. announced the poll results of its 2024 Annual General Meeting and the 2025 First Class Meetings for various shareholders. While most resolutions were passed, a resolution at the H Shareholders Class Meeting was not approved. The meetings were conducted in compliance with relevant laws and regulations, and the results are considered lawful and valid. This announcement reflects the company’s ongoing governance processes and may impact its shareholder relations and strategic decisions moving forward.